Chloe Ramirez
The Epstein-Barr virus (EBV), a member of the herpes virus family, is one of the most common human viruses. It was the first virus shown to cause cancer in humans in 1964 and is also associated with other illnesses, including multiple sclerosis. EBV is estimated to cause approximately 200,000 cases of cancer globally per year, and about 95% of adults worldwide are infected with the virus. Despite this, there is currently no licensed vaccine against EBV, although extensive research is being conducted, and a few potential vaccines are in Phase I clinical trials.
| Characteristics | Values |
|---|---|
| Is there a vaccine for Epstein Barr Virus? | As of 2025, there is no licensed vaccine for Epstein Barr Virus (EBV). However, extensive research is being conducted to develop one. |
| EBV vaccine candidates | OPKO Health's ModeX Therapeutics has an EBV vaccine candidate that entered Phase I clinical study in 2025. |
| EBV vaccine development | Researchers have identified vulnerable sites on the EBV protein gp42 that could be targeted to elicit antibodies and prevent infection. Another vaccine candidate uses nanoparticles displaying gH/gL from EBV to provide cross-protection against rhesus lymphocryptovirus. |
| EBV vaccine potential benefits | An EBV vaccine could potentially prevent Multiple Sclerosis (MS) and reduce the risk of certain cancers such as nasopharyngeal carcinoma and B-cell lymphomas. |
Explore related products
What You'll Learn
Potential to prevent multiple sclerosis
While there is currently no licensed vaccine against the Epstein-Barr virus (EBV), there is extensive research underway to develop one. EBV is a highly contagious herpes virus that spreads primarily through saliva and has been linked to cancers and autoimmune diseases such as multiple sclerosis (MS).
MS is an autoimmune disease where a type of immune cell called a T cell attacks the myelin, the protective covering around nerves in the brain and spinal cord, leading to physical and neurological symptoms that progress over time. While the exact cause of MS is unknown, researchers have long suspected a link between MS and EBV infection. A 2022 longitudinal analysis revealed a high prevalence of EBV associated with MS, and a 2025 study by the National Institutes of Health (NIH) supported this, finding that EBV infection significantly increased the likelihood of developing MS.
The potential connection between EBV and MS has important implications for the development of an EBV vaccine and its potential to prevent MS. Researchers are exploring the possibility that vaccinating children before they are exposed to EBV could prevent MS from developing in those who are genetically predisposed to the disease. This is similar to how vaccines have successfully eliminated diseases like measles and polio in the US.
The development of an EBV vaccine could be a significant breakthrough in preventing MS, but more research is needed to confirm the link between the virus and the disease.
EMT Tetanus Shots: How Often for Prophylaxis?
You may want to see also
Explore related products
Blocking EBV cell entry
The Epstein-Barr virus (EBV) is a highly contagious human herpesvirus that spreads primarily through saliva. It was the first virus shown to cause cancer in humans in 1964 and is linked to various cancers and autoimmune diseases. Despite being discovered 60 years ago, there is still no licensed vaccine against EBV.
EBV infects B cells of the immune system, epithelial cells, and may infect T cells, NK cells, and histiocytic-dendritic cells. The infection rate of EBV in the global population is over 90%. EBV infects B cells by binding to the cellular receptor CD21 (CR2) through its viral glycoprotein gp350. Subsequently, viral glycoprotein gp42 interacts with cellular MHC class II molecules, triggering fusion with the cell membrane and allowing EBV entry.
To block EBV cell entry, researchers have targeted the viral glycoproteins and antibodies involved in the process. For instance, antibodies to gp350, such as 72A1, can block CD21 receptor binding on B cells, preventing EBV-positive tumours and reducing the rate of EBV infection during liver transplantation. Additionally, antibodies blocking the EBV fusion machinery (targeting gH/gL or gB) have successfully prevented EBV infection and disease in humanized mice.
Another approach to blocking EBV cell entry involves the use of monoclonal antibodies (mAbs) that target the core fusion machinery. For example, mAb A10 effectively blocks an early step of virus entry by inhibiting receptor binding and fusion with B cells. In contrast, mAb 4C12 targets a hydrophobic pocket on gp42, responsible for membrane fusion, without affecting receptor binding. These studies provide valuable insights into the mechanisms of EBV cell entry and offer potential strategies for vaccine development.
Furthermore, Dr Andrew McGuire and his team have made significant progress by evaluating a vaccine made of nanoparticles displaying the viral proteins gH/gL, which are essential for EBV cell entry. The vaccine aims to train the immune system to recognize and generate antibodies against these proteins, thereby preventing EBV cell entry and infection. While this research is promising, it is still in the early stages, and further studies are needed to confirm the efficacy of this approach in blocking EBV cell entry and developing an effective vaccine.
Hepatitis A Vaccine: Lifetime Immunity or Booster Needed?
You may want to see also
Explore related products
Preventing EBV infection in humans
Despite being discovered 60 years ago, there is still no licensed vaccine to prevent Epstein-Barr virus (EBV) infection in humans. EBV is a highly contagious herpes virus that spreads primarily through saliva and has an infection rate of over 90% in the global population. It is the first virus shown to cause cancer in humans and is linked to various malignancies and autoimmune disorders, including multiple sclerosis (MS).
However, extensive research is being conducted to develop an EBV vaccine, and recent studies have shown promising results. For instance, a study by Dr. Andrew McGuire and his team at Fred Hutchinson Cancer Center evaluated the efficacy of a vaccine made of nanoparticles displaying 60 copies of the viral proteins required for cell entry, known as gH/gL. The vaccine aims to train the immune system to recognize and generate antibodies against the gH/gL proteins, thereby preventing EBV cell entry and infection. Another study by Australian researchers published in Nature Communications describes a highly effective EBV vaccine in laboratory models, targeting multiple parts of the virus and inducing strong, long-lasting immunity in two vital arms of the immune system.
Additionally, OPKO Health's ModeX Therapeutics has announced a collaboration with Merck to develop an EBV vaccine candidate, MDX2201, which has entered Phase I clinical trials. This vaccine is based on ModeX's ferritin nanoparticle vaccine platform and can express multiple copies of a recombinant antigen to stimulate protective immunity. Furthermore, researchers are also exploring the development of therapeutic vaccines that could help treat MS by targeting EBV-infected B cells, which are believed to contribute to the disease.
While there is currently no licensed vaccine to prevent EBV infection, the ongoing research and clinical trials bring hope that an effective vaccine may be within reach in the future.
Vaccination Policy: A Collective Action Problem
You may want to see also
Explore related products
EBV vaccine candidates in Phase I clinical trials
Despite extensive research and numerous clinical trials, there is currently no licensed vaccine against the Epstein-Barr virus (EBV). EBV is a highly contagious herpes virus that spreads primarily through saliva. It is the first identified oncogenic virus, which establishes permanent infection in humans and is linked to various cancers and autoimmune diseases.
Several vaccine candidates are in Phase I clinical trials to evaluate their safety, tolerability, and immunogenicity. Here is some information about the EBV vaccine candidates in Phase I trials:
MRNA-1189 (Moderna)
This is an mRNA-based vaccine candidate developed by Moderna, which contains four mRNAs encoding EBV envelope glycoproteins (gH, gL, gp42, and gp220). These glycoproteins mediate viral entry into B-cells and epithelial surface cells, the primary targets of EBV infection. The Phase 1 trial, known as Eclipse, began in January 2022 and involved healthy adults aged 18-30. Participants received three intramuscular injections of mRNA-1189 at different dose levels, and the vaccine was found to be immunogenic and well tolerated.
Gp350-ferritin nanoparticle vaccine
This vaccine candidate is formulated with recombinant EBV gp350 and aims to evaluate vaccine safety and immunogenicity. A Phase I trial recruited children with chronic kidney disease awaiting organ transplantation. The children received two different doses (12.5 and 25 μg) of recombinant gp350 with alum, and specific IgGs were found in all subjects. However, neutralizing antibodies were detected in only a few subjects, and the vaccination did not affect the post-transplant immune condition.
EBNA-3 epitope-based vaccine
This vaccine was tested in a Phase I trial on 14 HLA B*0801-positive, EBV-seronegative adults. It consisted of an EBNA-3 CD8+ epitope combined with tetanus toxoid and Montanide ISA 720 as the adjuvant. The vaccine was found to be safe, and epitope-specific responses were observed, but some immunized subjects seroconverted asymptomatically.
While these Phase I trials have shown promising results, more research and larger trials are needed to develop an effective vaccine against EBV.
Equine Vaccines: 5-Way Protection for Horses
You may want to see also
Explore related products
EBV vaccine technology and innovation
Despite being discovered 60 years ago, there is still no licensed vaccine against the Epstein-Barr virus (EBV). EBV is a highly contagious herpes virus that spreads primarily through saliva and infects over 90% of the global population. It is the primary cause of mononucleosis and is also linked to cancers and autoimmune diseases such as multiple sclerosis (MS).
The development of an EBV vaccine is a significant area of research, with scientists exploring various approaches and innovations to prevent and treat EBV infections. One notable innovation is the use of nanoparticles to display the viral proteins required for cell entry, specifically the gH/gL proteins. Dr Andrew McGuire and his team have made significant progress in this area, evaluating the efficacy of a vaccine made of nanoparticles displaying 60 copies of the gH/gL proteins, using two adjuvants to enhance the immune response. The vaccine aims to train the immune system to recognise and generate antibodies against the gH/gL proteins, thereby preventing EBV cell entry and infection.
Another innovation in EBV vaccine technology is the multi-targeted approach developed by OPKO Health's ModeX Therapeutics. Their vaccine candidate, MDX2201, is based on a ferritin nanoparticle vaccine platform that can express multiple copies of recombinant antigens to enhance the presentation of key components of the virus and stimulate protective immunity. This approach targets both B cells and epithelial cells, inhibiting infection in both cell types.
Additionally, Australian researchers have developed a highly effective EBV vaccine that targets multiple parts of the virus, inducing strong and long-lasting immunity in two vital arms of the immune system. Their approach uses components from several EBV viral proteins to achieve wide immune coverage across various stages of infection, stimulating both the B cells and T cells arms of the immune system.
These innovations in EBV vaccine technology demonstrate the significant progress being made towards developing an effective vaccine. While there is still much work to be done, these advancements offer hope for preventing and treating EBV infections, reducing the global burden of EBV-associated diseases, and potentially lowering the risk of developing MS and other autoimmune disorders.
The End of Polio Sugar Cubes
You may want to see also
Frequently asked questions
No, there is currently no licensed vaccine for EBV.
EBV is a highly contagious virus that spreads primarily through saliva. It is estimated to cause approximately 200,000 cases of cancer globally per year and is also linked to autoimmune diseases such as multiple sclerosis.
Researchers at QIMR Berghofer have developed a new EBV vaccine that has shown to be highly effective in laboratory models. Two Phase I clinical trials are currently underway to test the safety and immune response of two EBV vaccines.
One of the challenges in developing an EBV vaccine is that the virus has multiple stages of infection and produces various proteins during each stage. Additionally, EBV remains in the body permanently, making it difficult to eradicate once an infection has occurred.
